908 Devices Inc.
NASDAQ•MASS
CEO: Dr. Kevin J. Knopp Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2020-12-18
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
連絡先情報
時価総額
$225.12M
PER (TTM)
11.6
26.5
配当利回り
--
52週高値
$9.34
52週安値
$3.55
52週レンジ
順位45Top 56.8%
3.6
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 3.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025
財務ダッシュボード
Q4 2025 データ
売上高
$17.38M+0.00%
直近4四半期の推移
EPS
$0.12+0.00%
直近4四半期の推移
フリーCF
$1.33M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Revenue Increased 15% Total revenue reached $56.20M in 2025, marking a $8.45M increase compared to $47.75M reported in 2024.
Continuing Operations Loss Narrows Net loss from continuing operations improved substantially to $(33.3M) in 2025, down from a $(53.1M) loss in the prior year.
Product Sales Grew 22% Product revenue increased 22% to $43.3M, primarily driven by strong performance of FTIR products like VipIR.
Cumulative Device Placements Grow Cumulative handheld device placements reached 3,736 units by year-end 2025, indicating successful market penetration.
リスク要因
History of Net Losses Persists Company has history of net losses; cannot assure ability to achieve profitability or sustain positive operating cash flow in future.
Macroeconomic Conditions Create Uncertainty Global economic uncertainty, inflation, and interest rates pressure customer spending patterns, potentially impacting financial condition.
Supply Chain Component Reliance Reliance on limited suppliers for key components risks delays or increased costs if access is limited or interrupted.
Intellectual Property License Dependency Business materially affected if in-bound license rights are lost or if disputes arise, limiting product development capabilities.
見通し
Drive Enterprise Adoption Strategy Intends to aggressively invest in field applications to accelerate post-sale partnerships and drive enterprise-wide adoption.
Expand Global Commercial Channels Focus on expanding domestic direct sales and growing international channel partners to support planned device sales growth.
Maintain R&D Investment Level Expects to maintain substantial investment in R&D to expand applications and introduce new products into new markets.
Cash Position Supports 12 Months Existing cash and equivalents of $70.5M are expected to fund operating expenses and capital needs for at least 12 months.
同業比較
売上高 (TTM)
$206.13M
$138.73M
$134.48M
粗利益率 (最新四半期)
162.0%
87.3%
86.3%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CAPR | $1.43B | -14.5 | -0.1% | 4.1% |
| ACRS | $467.91M | -7.3 | -52.0% | 1.3% |
| NPCE | $465.28M | -21.1 | -105.7% | 67.1% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
13.9%
安定成長
4四半期純利益CAGR
-54.2%
収益性の低下
キャッシュフロー安定性
25%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月11日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし